Although the oncogenic cascade of ATLL is not yet fully elucidated, it has been suggested that describing the mechanisms of expression of SOX4 more clearly could reveal its potential as a therapeutic target molecule. The gene discussed is SOX4; the disease is adult T-cell leukemia/lymphoma.